PMID- 27809798
OWN - NLM
STAT- MEDLINE
DCOM- 20170926
LR  - 20220408
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 16
IP  - 1
DP  - 2016 Nov 3
TI  - Increased serum amyloid A as potential diagnostic marker for lung cancer: a 
      meta-analysis based on nine studies.
PG  - 836
LID - 836
AB  - BACKGROUND: Previous studies have disclosed that serum amyloid A (SAA) is likely 
      involved in the lung cancer pathogenesis and progression. We performed a 
      systematic evaluation and meta-analysis to disclose the correlation between the 
      expression of SAA and lung cancer and to evaluate its value for lung cancer 
      diagnosis. METHODS: We searched the relevant articles from the databases of 
      Medline, Embase, Cochrance Library and Web of Science and calculated the 
      standardized mean difference (SMD) with 95 % confidence interval (CI) to assess 
      the expression difference of SAA between lung cancer and normal patients. 
      Moreover, we counted the positive rate, sensitivity and specificity and drew a 
      summary receiver operating characteristic curve (SROC) to evaluate the diagnostic 
      value of SAA for lung cancer. RESULTS: A total of nine studies with 1392 
      individuals were included in this analysis. The results showed an increased SAA 
      was correlated with the incidence of lung cancer (P < 0.001), especially with the 
      lung squamous cell carcinoma (LSCC) (p = 0.012). The overall sensitivity and 
      specificity of SAA for discerning lung cancer was 0.59 (95 % CI: 0.54-0.63) and 
      0.92 (95 % CI: 0.88-0.95), respectively. The area under the SROC curve was 0.9066 
      (SE = 0.0437). CONCLUSIONS: Increased SAA in lung cancer was intimately 
      correlated with the development and progression of lung cancer. A higher 
      specificity of SAA suggested that it should be a significant biomarker for 
      discerning lung cancer from normal individuals, especially for LSCC (p = 0.012).
FAU - Biaoxue, Rong
AU  - Biaoxue R
AD  - Department of Respiratory Medicine, First Affiliated Hospital, Xi'an Medical 
      University, 48 Fenghao West Road, Xi'an, 710077, China. research568rbx@yeah.net.
AD  - Research Center of Prevention and Treatment of Respiratory Disease, Xi'an, 
      Shaanxi Province, 710077, China. research568rbx@yeah.net.
FAU - Hua, Liu
AU  - Hua L
AD  - Department of Respiratory Medicine, Gansu Provincial Hospital, Lanzhou, China.
FAU - Wenlong, Gao
AU  - Wenlong G
AD  - Department of Statistics and Epidemiology, Medical College, Lanzhou University, 
      Lanzhou, China.
FAU - Shuanying, Yang
AU  - Shuanying Y
AD  - Department of Respiratory Medicine, Second Affiliated Hospital, Xi'an Jiaotong 
      University, Xi'an, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20161103
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Serum Amyloid A Protein)
SB  - IM
MH  - Biomarkers, Tumor/*blood
MH  - Disease Progression
MH  - Humans
MH  - Lung Neoplasms/blood/*diagnosis
MH  - Prognosis
MH  - Serum Amyloid A Protein/*metabolism
PMC - PMC5093952
OTO - NOTNLM
OT  - Diagnosis
OT  - Lung cancer
OT  - Meta-analysis
OT  - SAA
OT  - Serum amyloid A
EDAT- 2016/11/05 06:00
MHDA- 2017/09/28 06:00
PMCR- 2016/11/03
CRDT- 2016/11/05 06:00
PHST- 2016/07/27 00:00 [received]
PHST- 2016/10/24 00:00 [accepted]
PHST- 2016/11/05 06:00 [pubmed]
PHST- 2017/09/28 06:00 [medline]
PHST- 2016/11/05 06:00 [entrez]
PHST- 2016/11/03 00:00 [pmc-release]
AID - 10.1186/s12885-016-2882-0 [pii]
AID - 2882 [pii]
AID - 10.1186/s12885-016-2882-0 [doi]
PST - epublish
SO  - BMC Cancer. 2016 Nov 3;16(1):836. doi: 10.1186/s12885-016-2882-0.